At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
Depemokimabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single Dose Study to Investigate the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Two Dose Levels of GSK3511294 Administered Subcutaneously in Chinese Healthy Participants
In Brief
A Phase 1 clinical trial evaluating Depemokimab for Asthma. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This single dose pharmacokinetic (PK) study aims to investigate the PK, safety, tolerability and immunogenicity of two dose levels of GSK3511294 administered subcutaneously in Chinese healthy participants
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartDec 2021
Primary CompletionDec 2022
TodayJul 2026
First PostedDec 1, 2021
Enrollment StartDec 10, 2021
Primary CompletionDec 23, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 4.6 years ago
Interventions
Depemokimabbiological
Depemokimab was administered.